Authors:
RICHARD MA
GROB JJ
ZARROUR H
BASSERES N
BIZZARI JP
GERARD B
BONERANDI JJ
Citation: Ma. Richard et al., COMBINED TREATMENT WITH DACARBAZINE, CISPLATIN, FOTEMUSTINE AND TAMOXIFEN IN METASTATIC MALIGNANT-MELANOMA, Melanoma research, 8(2), 1998, pp. 170-174
Authors:
LECHEVALIER T
BERILLE J
OLIVARES R
BRUNO R
HAMMERSHAIMB L
BIZZARI JP
Citation: T. Lechevalier et al., SERUM ALPHA-1-ACID GLYCOPROTEIN (AAG) IS AN INDEPENDENT PROGNOSTIC FACTOR FOR EFFICACY AND SURVIVAL IN PATIENTS WITH INOPERABLE NON-SMALL-CELL LUNG-CANCER (NSCLC) TREATED WITH TAXOTERE(R), Annals of oncology, 9, 1998, pp. 414-414
Authors:
KHAYAT D
BANZET P
WEIL M
FUMOLEAU P
AVRIL MF
NAMER M
BONNETERRE J
KERBRAT P
BONERANDI JJ
BUGAT R
MONTCUQUET P
CUPISSOL D
LAUVIN R
VILMER C
BOAZIZ C
COUR V
BIZZARI JP
Citation: D. Khayat et al., FOLLOW-UP OF 153 MELANOMA EVALUABLE PATIENTS TREATED BY FOTEMUSTINE -PROGNOSIS FACTORS FOR RESPONSE AND SURVIVAL, Medicamentos de actualidad, 32, 1996, pp. 35-41
Authors:
RIXE O
BOREL C
PARAISO D
BENHAMMOUDA A
PETIT T
ANTOINE E
BIZZARI JP
AUCLERC G
SOUBRANE C
WELL M
GIROUX B
BANZET P
KHAYAT D
Citation: O. Rixe et al., FOTEMUSTINE, DACARBAZINE, VINDESINE COMBINATION CHEMOTHERAPY IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF 43 PATIENTS, Melanoma research, 5(6), 1995, pp. 419-424
Authors:
SOUDON J
BERLION M
LUCAS C
HADDAD P
BIZZARI JP
CALVO F
Citation: J. Soudon et al., IN-VITRO ACTIVITY OF S-9788 ON A MULTIDRUG-RESISTANT LEUKEMIC-CELL LINE AND ON NORMAL HEMATOPOIETIC CELLS-REVERSAL OF MULTIDRUG-RESISTANCE BY SERA FROM PHASE-I TREATED PATIENTS, Cancer chemotherapy and pharmacology, 36(3), 1995, pp. 195-203
Authors:
RIXE O
BENHAMMOUDA A
ANTOINE E
PETIT T
TOURANI JM
BOREL C
FRANKS C
KALIF B
MOUSSEAU M
THOMAS A
BENSFIA S
NIZRI D
SOUBRANE C
HERRERA A
BIZZARI JP
AUCLERC G
WEIL M
BANZET P
KHAYAT D
Citation: O. Rixe et al., CHEMOIMMUNOTHERAPY OF METASTATIC MELANOMA - CISPLATIN, INTERLEUKIN-2 AND IFN-ALPHA IN 91 PATIENTS, Pathologie et biologie, 42(10), 1994, pp. 1080-1081
Authors:
SOUBRANE C
MOUAWAD R
ICHEN M
SUISSA J
BOREL C
VUILLEMIN E
BENHAMMOUDA A
BIZZARI JP
WEIL M
KHAYAT D
Citation: C. Soubrane et al., FOLLOW-UP OF SOLUBLE IL-2 RECEPTOR LEVEL IN METASTATIC MALIGNANT-MELANOMA PATIENTS TREATED BY CHEMOIMMUNOTHERAPY, Clinical and experimental immunology, 95(2), 1994, pp. 232-236
Authors:
FISCHEL JL
BARBE V
BERLION M
FORMENTO P
BERRILE J
BIZZARI JP
MILANO G
Citation: Jl. Fischel et al., TAMOXIFEN ENHANCES THE CYTOTOXIC EFFECTS OF THE NITROSOUREA FOTEMUSTINE - RESULTS ON HUMAN-MELANOMA CELL-LINES, Bulletin du cancer, 81(7), 1994, pp. 599-604
Authors:
OUMHAMED Z
BERLION M
MILLOTBROGLIO C
DUFER J
JOLY P
BIZZARI JP
DESPLACES A
Citation: Z. Oumhamed et al., QUANTITATIVE CYTOLOGICAL STUDY OF THE ACT IVITY OF A NEW RESISTANCE MODULATOR, S-9788, ON HUMAN LEUKEMIC-CELLS USING MULTIPARAMETRIC IMAGE-ANALYSIS, Bulletin du cancer, 81(3), 1994, pp. 203-211
Authors:
PUJOL JL
MONNIER A
BERILLE J
CERRINA ML
DOUILLARD JY
RIVIERE A
GRANDGIRARD A
GOUVA S
BIZZARI JP
LECHEVALIER T
Citation: Jl. Pujol et al., PHASE-II STUDY OF NITROSOUREA FOTEMUSTINE AS SINGLE-DRUG CHEMOTHERAPYIN POOR-PROGNOSIS NON-SMALL-CELL LUNG-CANCER, British Journal of Cancer, 69(6), 1994, pp. 1136-1140
Authors:
JULIA AM
ROCHE H
BERLION M
LUCAS C
MILANO G
ROBERT J
BIZZARI JP
CANAL P
Citation: Am. Julia et al., MULTIDRUG-RESISTANCE CIRCUMVENTION HY A NEW TRIAZINOAMINOPIPERIDINE DERIVATIVE S9788 IN-VITRO - DEFINITION OF THE OPTIMAL SCHEDULE AND COMPARISON WITH VERAPAMIL, British Journal of Cancer, 69(5), 1994, pp. 868-874
Authors:
FISCHEL JL
BARBE V
BERLION M
FORMENTO P
BERRILE J
BIZZARI JP
MILANO G
Citation: Jl. Fischel et al., TAMOXIFEN ENHANCES THE CYTOTOXIC EFFECTS OF THE NITROSOUREA FOTEMUSTINE - RESULTS ON HUMAN-MELANOMA CELL-LINES, European journal of cancer, 29A(16), 1993, pp. 2269-2273
Authors:
FISCHEL JL
BERLION M
FORMENTO P
BIZZARI JP
MILANO G
Citation: Jl. Fischel et al., EVALUATION OF THE TIME-SCHEDULE DEPENDENCY FOR THE CYTOTOXIC ACTIVITYOF THE NEW VINCA ALKALOID DERIVATIVE, S-12363 (VINFOSILTINE), European journal of cancer, 29A(13), 1993, pp. 1890-1894
Authors:
LASSET C
MERROUCHE Y
NEGRIER S
REBATTU P
BERILLE J
BIZZARI JP
CHAUVIN F
PHILIP T
Citation: C. Lasset et al., PHASE-II STUDY OF FOTEMUSTINE AS 2ND-LINE TREATMENT AFTER FAILURE OF IMMUNOTHERAPY IN METASTATIC RENAL-CELL CARCINOMA, Cancer chemotherapy and pharmacology, 32(4), 1993, pp. 329-331